These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 19956885

  • 1. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H, Igishi T, Ueda Y, Shigeoka Y, Kodani M, Morita M, Takeda K, Sumikawa T, Nakazaki H, Matsunami K, Matsumoto S, Shimizu E.
    Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
    [Abstract] [Full Text] [Related]

  • 2. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.
    Cancer Res; 2002 Nov 01; 62(21):6304-11. PubMed ID: 12414661
    [Abstract] [Full Text] [Related]

  • 3. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, García-Echeverría C, Krystal GW.
    Mol Cancer Ther; 2004 May 01; 3(5):527-35. PubMed ID: 15141010
    [Abstract] [Full Text] [Related]

  • 4. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW, Honsawek S, Litz J, Buchdunger E.
    Clin Cancer Res; 2000 Aug 01; 6(8):3319-26. PubMed ID: 10955819
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
    Cancer Res; 2005 Sep 15; 65(18):8423-32. PubMed ID: 16166321
    [Abstract] [Full Text] [Related]

  • 6. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
    Maulik G, Bharti A, Khan E, Broderick RJ, Kijima T, Salgia R.
    J Environ Pathol Toxicol Oncol; 2004 Sep 15; 23(4):237-51. PubMed ID: 15511212
    [Abstract] [Full Text] [Related]

  • 7. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 8. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.
    Clin Cancer Res; 2005 Feb 15; 11(4):1563-71. PubMed ID: 15746061
    [Abstract] [Full Text] [Related]

  • 9. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 15; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 10. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
    Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF.
    Int J Cancer; 2005 Feb 20; 113(5):849-56. PubMed ID: 15499612
    [Abstract] [Full Text] [Related]

  • 11. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
    Ueda Y, Igishi T, Hashimoto K, Suyama H, Araki K, Sumikawa T, Takeda K, Nakazaki H, Matsunami K, Kodani M, Shigeoka Y, Matsumoto S, Shimizu E.
    Int J Oncol; 2009 Mar 20; 34(3):689-96. PubMed ID: 19212674
    [Abstract] [Full Text] [Related]

  • 12. Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
    Yoshida C, Niiya K, Niiya M, Shibakura M, Asaumi N, Tanimoto M.
    Blood Coagul Fibrinolysis; 2007 Jul 20; 18(5):425-33. PubMed ID: 17581316
    [Abstract] [Full Text] [Related]

  • 13. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
    Litz J, Krystal GW.
    Mol Cancer Ther; 2006 Jun 20; 5(6):1415-22. PubMed ID: 16818499
    [Abstract] [Full Text] [Related]

  • 14. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA, Laug WE, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2003 Oct 20; 52(4):307-18. PubMed ID: 12827297
    [Abstract] [Full Text] [Related]

  • 15. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T.
    Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW, Sulanke G, Litz J.
    Mol Cancer Ther; 2002 Sep 01; 1(11):913-22. PubMed ID: 12481412
    [Abstract] [Full Text] [Related]

  • 17. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
    Krasagakis K, Fragiadaki I, Metaxari M, Krüger-Krasagakis S, Tzanakakis GN, Stathopoulos EN, Eberle J, Tavernarakis N, Tosca AD.
    J Cell Physiol; 2011 Apr 01; 226(4):1099-109. PubMed ID: 20857409
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 19. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.
    Mol Cancer Ther; 2003 May 15; 2(5):471-8. PubMed ID: 12748309
    [Abstract] [Full Text] [Related]

  • 20. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
    Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY.
    Oncogene; 2001 Jun 28; 20(29):3845-56. PubMed ID: 11439348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.